Louisville, KY – February 16, 2010 – In recognition of rapidly growing applications in a variety of research and drug development areas, Peptides International, Inc. has announced the launch of a comprehensive RGD TECHNOLOGY PLATFORM. The new Platform recognizes and seamlessly integrates the Company’s expertise in large-scale production of cyclic-RGD peptides, dimeric and tetrameric derivatives, RGD chelated conjugates for radiolabeled tumor targeting and imaging, with its industry-leading portfolio of commercial RGD products.
In announcing the launch, Dr. Bryce V. Johnson, Ph.D., President & CEO said, “This technology platform will allow a researcher in the field to collaborate with PI and use our expertise and experience to make complex prototypes, scale them up and, if needed, complement them with a wide variety of existing commercial RGD peptides. In doing this, we hope the platform will facilitate investigators’
Proteins that contain the Arg-Gly-Asp (RGD) sequence, together with the integrins that serve as receptors for them, play a special role in cell recognition and related processes such as angiogenesis or endothelial apoptosis. RGD related peptides are important tools for research including drug design and development, preparation of radiolabeled derivatives for tumor targeting and imaging, and in novel biomaterials development.
Peptides International Inc. (PEPNET.COM)
Contact:
DeAnna W. Long, Ph.D.
Director of Sales and Marketing
Peptides International, Inc.
11621 Electron Drive
Louisville, Kentucky 40299 USA
Phone: 502-266-
Fax: 502-267-
E-mail:
Website:
Photo:
http://www.prlog.org/
